One-shot weight loss: Can gene therapy actually replace the GLP-1 revolution?
Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to […]
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss plateau 54% of participants on the 24 mg dose achieved resolution of obesity (BMI <30 kg/m2) vs. 13% in the placebo group […]
Cipla plans deeper push in domestic market and chronic therapies over next 2–3 years
Cipla’s incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presence and pursuing selective inorganic growth and innovation. The company aims to strengthen its respiratory leadership and achieve similar dominance in cardiometabolic diseases and obesity, with a near-term focus on the GLP-1 weight-loss segment through its partnership with […]
罗氏实验性肥胖症药物在II期临床试验中取得积极结果
Roche”s experimental obesity drug delivers positive phase II results (www.reuters.com) 15:03
Can Diabetes And Obesity Drugs Help Treat Psychiatric Disorders?
A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving overall health and possibly extending survival in people with serious…
Patients Microdose GLP-1s Without Clinician Input
A larger percentage of GLP-1 users say social media and online research are their most trusted source for microdosing information over their clinician. Medscape Medical News
Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta-analysis to compare the efficacy of emerging and established HFpEF therapies. Materials and Methods We systematically searched PubMed, Embase […]
Amanda Bynes looks unrecognizable as she shows off weight loss after Ozempic admission
CHILD star Amanda Bynes looks slimmer than ever in a new video after revealing she has been using weight loss jabs. At the end of last year, Amanda, 39, revealed that she had been using a GLP-1 to shed weight – and now she is flaunting the results. She posted a paparazzi photo on her…
Pfizer’s CEO on leading after a moonshot—and making deals with Trump
In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s incoming CEO speaks out about the immigration crackdown in the retailer’s home state. The markets: Up globally, with U.S. markets set to climb at the open. Plus: All the news and watercooler chat from Fortune. Good morning. What […]